Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia

• Status: Not yet recruiting
• Trial end date: 2022-01-31

Summary

This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia. Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to control febrile neutropenia in patients with cancer.

• Phase: Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Cefepime; Cilastatin; Daptomycin; Imipenem; Linezolid; Meropenem; MK-7655; Piperacillin; Piperacillin, Tazobactam Drug Combination; Relebactam; Tazobactam; Vancomycin